Advisers voted unanimously to recommend a third dose of Pfizer’s vaccine in people 65 and older and those at high risk of severe Covid-19

The decision came after members of the FDA’s Vaccines and Related Biological Products Advisory Committee rejected a broader application to approve booster doses of Pfizer’s vaccines in everyone 16 and … Read More

Loading

Follow by Email
Pinterest
LinkedIn
Share